에서 실시간으로 운영 중이에요! 자세히 알아보기

Moderna

MRNA

시가총액 US$870억

218.01 USD

-18.49

7.82%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

215.80

-2.21

1.01%

1일

-7.82%

5일

-2.89%

1개월

49.71%

3개월

245.23%

6개월

298.7%

연초 이후

606.45%

1년

703.28%

5년

-34.89%

10년

1,072.1%

소개: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

직원 수: 4,700

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 57.5%

중립 25.7%

부정적 16.9%

Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather

Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.

Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather

Why is Moderna down 10% on Friday?

Moderna MRNA shares suffered a sharp reversal on Friday, falling close to 10% after a strong October rally had pushed the biotechnology to its 52-week high. The shares, which reached $242.29 during their recent advance, were trading near $213 at the time of writing.

Why is Moderna down 10% on Friday?

24/7 Wall Street

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developers.

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

24/7 Wall Street

Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put

Profit taking is hitting one of biotech's hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 10% to $214.

Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put

The Motley Fool

Meet the New Nasdaq-100 Stock That's Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?

AI stocks have been known for explosive gains in recent years and have driven the S&P 500 higher. This year, some investors scored a much bigger win by investing in a promising biotech stock.

Meet the New Nasdaq-100 Stock That's Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?

Moderna: Best S&P 500 Stock YTD Could Rally Into YE, But Valuation Is Uncertain

Moderna has staged a dramatic rebound, becoming the best-performing S&P 500 stock YTD, driven by pipeline optimism and strong technical momentum. I maintain a "Hold" rating on MRNA due to persistent unprofitability, negative free cash flow, and a valuation highly dependent on pipeline execution. Key catalysts include upcoming Q3 earnings on November 6 and Analyst Day on November 12, with high implied volatility and significant event-driven price risk.

Moderna: Best S&P 500 Stock YTD Could Rally Into YE, But Valuation Is Uncertain

Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks

Shares of Nike Inc. (NYSE:NKE), Moderna Inc. (NASDAQ:MRNA) and Walmart Inc. (NASDAQ:WMT) climbed Thursday as money flowed out of tech and AI stocks for a second straight session.

Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks

24/7 Wall Street

Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher

Healthcare is drawing fresh buying as money moves away from the market's popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are up 6% to $239.

Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher

Bloomberg Markets and Finance

Moderna, Google DeepMind, Biocon on AI in Science

Noubar Afeyan, Co-Founder & Chairman, Moderna and Founder & CEO, Flagship Pioneering; Lila Ibrahim, Chief AI Readiness Officer, Google DeepMind; and Kiran Mazumdar-Shaw, Founder & Executive Chairperson, Biocon discuss how AI is reshaping scientific discovery with Bloomberg's Francine Lacqua at the 2026 Bloomberg New Economy Forum in New Delhi. -------- More on Bloomberg Television and Markets Like this video?

Moderna, Google DeepMind, Biocon on AI in Science

24/7 Wall Street

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers you need to see first.

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.